openPR Logo
Press release

Investigation announced for Investors in Aytu BioScience, Inc. (NASDAQ: AYTU)

01-26-2022 04:43 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Aytu BioScience, Inc. (NASDAQ: AYTU) shares over potential securities laws violations.

An investigation for investors in Aytu BioScience, Inc. (NASDAQ: AYTU) shares over potential securities laws violations.

An investigation on behalf of investors of Aytu BioScience, Inc. (NASDAQ: AYTU) shares over potential securities laws violations by Aytu BioScience, Inc. (NASDAQ: AYTU and certain of its directors and officers in connection with certain financial statements was announced.

Investors who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Aytu BioScience, Inc. (NASDAQ: AYTU) concerning whether a series of statements by Aytu BioScience, Inc. (NASDAQ: AYTU regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Englewood, CO based Aytu BioPharma, Inc. , a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. Aytu BioScience, Inc. reported that its Total Revenue rose from $27.63 million for the 12 months period that ended on June 30, 2020 to $65.63 million for the 12 months period that ended on June 30, 2021, and that its Net Loss over those respective time periods increased from $13.62 million to $58.28 million..

Shares of Aytu BioScience, Inc. (NASDAQ: AYTU) declined from $29.90 per share in March 2020 to as low as $1.06 per share on January 24, 2022.

Those who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Aytu BioScience, Inc. (NASDAQ: AYTU) here

News-ID: 2538337 • Views: 249

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Graphite Bio, Inc. (NASDAQ: G …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Graphite Bio, Inc. Investors who purchased shares of Graphite Bio, Inc. (NASDAQ: GRPH) and currently hold any of those NASDAQ: GRPH shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Graphite Bio, Inc. directors breached their fiduciary duties and caused
Romeo Power, Inc. (NYSE: RMO) Investor Notice: Update in Lawsuit against Romeo P …
The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in shares of Romeo Power, Inc. (NYSE: RMO). Investors who are current long term investors in Romeo Power, Inc. (NYSE: RMO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On April 16, 2021, a lawsuit was filed against Romeo Power, Inc. over alleged securities laws violations.
Investigation announced for Long-Term Investors in Standard Lithium Ltd. (NYSE: …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Standard Lithium Ltd. Investors who are current long-term investors in Standard Lithium Ltd. (NYSE: SLI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long-term investors in NYSE: SLI stocks follows a lawsuit filed against Standard Lithium Ltd. over
Match Group, Inc. (NASDAQ: MTCH) Shareholder Notice: Update in Lawsuit against M …
The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in Match Group, Inc. (NASDAQ: MTCH). Investors who purchased shares of Match Group, Inc. (NASDAQ: MTCH) and currently hold any of those NASDAQ: MTCH shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On October 3, 2019, a lawsuit was filed against Match Group Inc over alleged

All 5 Releases


More Releases for Aytu

Aytu BioScience, Inc. (NASDAQ: AYTU) Investor Investigation over possible Securi …
An investigation was announced concerning potential securities laws violations by Aytu BioScience, Inc. in connection with certain financial statements. Investors who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Aytu BioScience, Inc. (NASDAQ: AYTU regarding its business, its prospects and its
GABA Receptor Agonist Market Astonishing Growth | Top Competitors like Sanofi, M …
"Data Bridge Market Research presents a detailed picture of the Global GABA Receptor Agonist Market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers." Data Bridge Market Research has recently added
Investigation for Investors in NASDAQ: AYTU shares over possible Wrongdoing at A …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Aytu BioScience, Inc. Investors who purchased shares of Aytu BioScience, Inc. (NASDAQ: AYTU) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Aytu BioScience directors breached their fiduciary duties and caused damage to the company and its shareholders. Englewood, CO
Global GABA Receptor Agonist Market Astonishing Growth | Top Competitors like Sa …
"Data Bridge Market Research presents a detailed picture of the Global GABA Receptor Agonist Market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers." Data Bridge Market Research has recently added
Cough Suppressant Drugs Market Development Industry 2019 Featuring with Top Play …
In March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Approval and launch of such new drugs in the market is expected to drive the cough suppressant drugs market growth over the forecast
Cough Suppressant Drugs Market Upcoming Opportunities, Growth, Scope Analysis by …
Cough suppressant drugs are used to suppress the cough. Cough is usually doesn't require any treatment as it goes away in few days. However cough medicines are required if it persists for more than a week and if it starts disturbing routine activities. Also, some types of cough help in clearing patients lungs and hence should not be treated with cough suppressant drugs. Hence consultation with the doctor before consumption